Arcutis appoints Neha Krishnamohan to Board of Directors and audit committee

Arcutis Biotherapeutics, Inc.

Board expanded from 9 to 10; Krishnamohan appointed Class III director and audit committee member.
Krishnamohan is CFO and EVP of Corporate Development at Kinnate Biopharma; previously VP at Goldman Sachs.
Received stock option for 29,482 shares vesting over three years; eligible for $40,000 annual retainer plus $10,000 for audit committee.
Krishnamohan worked on Arcutis' 2020 IPO while at Goldman Sachs.
Appointment effective September 2, 2022.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Neha Krishnamohan

Class III Director and Audit Committee Member

ARQT · Arcutis Biotherapeutics, Inc.

Effective: 2022-09-02
Filed: September 6, 2022, 7:59 PM ET

Effective as of September 2, 2022, the Board of Directors (the “Board”) of Arcutis Biotherapeutics, Inc. (the “Company”) increased the size of the Board from nine (9) directors to ten (10) directors and appointed Neha Krishnamohan to the Board as a new Class III director and as a member of the Audit Committee of the Board (the “Audit Committee”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Neha Krishnamohan was appointed as Class III Director and Audit Committee Member at Arcutis Biotherapeutics, Inc..

Action: appointed
Role: Class III Director and Audit Committee Member

Exact text from the filing

Effective as of September 2, 2022, the Board of Directors (the “Board”) of Arcutis Biotherapeutics, Inc. (the “Company”) increased the size of the Board from nine (9) directors to ten (10) directors and appointed Neha Krishnamohan to the Board as a new Class III director and as a member of the Audit Committee of the Board (the “Audit Committee”).

View on SEC.gov

Arcutis Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001787306-22-000057

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.